Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Molecular Partner…

CHCHF
← Naar de Screener

Molecular Partners AG (LSE:0QXX) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het Bedrijf

Website
molecularpartners.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hoofdkantoor
Schlieren-Zurich, Switzerland
CEO
Patrick Amstutz
Werknemers
134
Uitstaande Aandelen
38.31 mln.
Free Float
20.71 mln.
Marktkapitalisatie
127.56 mln. CHF
Insiders
8.47%
Institutionele Beleggers
43.8%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Rechtsvorm
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
FCF
−52.0 mln. CHF
Schuld
?
Winst en FCF — voor de 12 maanden tot 31.12.2025 (het laatste rapport van het bedrijf).
Beschrijving

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

advertentie

Beurzen en Tickers

BeursTickerValutaPrijsType
SW SIX Swiss ExchangeMOLN primairCHF3.33 -0.30%gewone aandelen
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%gewone aandelen
US USA StocksMLLCF OTCUSD4.01 +0.00%gewone aandelen

Koers over 3 Maanden

stijgingsdag dalingsdagBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Grootste Aandeelhouders

HouderBelangAandelenRapportdatum
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31